Lancet study reveals lower rates of stent thrombosis with cobalt-chromium everolimus eluting stents

Published date : 29 April 2012
Article date : 29 April 2012


 A network meta-analysis of randomised controlled trials comparing different drug-eluting stents, or drug-eluting with bare-metal stents, has revealed that cobalt-chromium everolimus eluting stents (CoCr-EES) deliver the lowest rate of stent thrombosis within two years of implantation. 
The 49 trial sample analysis includes results from more than 50,000 patients and revealed a number of findings. The incidence of 1-year definite stent thrombosis was significantly lower with CoCr-EES than with bare-metal stents (odds ratio [OR] 0·23, 95% CI 0·13—0·41). The significant difference between these stent classes was evident from as early as 30 days, and also in the 31 day - 1 year period. CoCr-EES were also linked to significantly lower rates of 1-year definite stent thrombosis  When compared with paclitaxel-eluting stents, permanent polymer-based sirolimus-eluting stents, phosphorylcholine-based zotarolimus-eluting stents, and Resolute zotarolimus-eluting stents.
No other drug-eluting stent had lower definite thrombosis rates compared with bare-metal stents at 2-year follow-up.
The full summary of this study can be found here.
Compare Which Medical Device listings for drug eluting stents here.


Back to Listings

WhichMedicalDevice is a FREE resource created by clinicians for clinicians.

Registration is free and gives you unlimited access to all of the content and features of this website.

Find out more...

Please sign in to view this content...

I have forgotten my password
Not a Member?

Registration is free and gives you unlimited access to all of the content and features of Which Medical Device. Find out more...

Why Register

Which Medical Device is a community of clinicians sharing knowledge and experience of the devices and procedures we use on a daily basis. We ask that our members register with us so that we can maintain the unbiased and independent nature of our content. Registration is quick and free.

We do not make your details available to any third parties nor do we send unsolicited emails to our members. You can read our Privacy Policy here.